Managing comorbid obesity and depression through clinical pharmacotherapies

References

• McElroy SL, Kotwal R, Malhotra S, et al. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry. 2004;65(5):634–651, quiz 730.
   PubMed Web of Science ®Google Scholar
• Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010 Mar;67(3):220–229.
   PubMed Web of Science ®Google Scholar
• McElroy SL. The epidemic of depression with obesity. J Clin Psychiatry. 2015 Oct;76(10):e1340–e1342.
   Google Scholar
• Simon GE, Von Korff M, Saunders K, et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry. 2006 Jul;63(7):824–830.
   PubMed Web of Science ®Google Scholar
• Petry NM, Barry D, Pietrzak RH, et al. Overweight and obesity are associated with psychiatric disorders: results from the national epidemiologic survey on alcohol and related conditions. Psychosom Med. 2008 Apr;70(3):288–297.
   PubMed Web of Science ®Google Scholar
• Goldstein BI, Liu SM, Zivkovic N, et al. The burden of obesity among adults with bipolar disorder in the United States. Bipolar Disord. 2011 Jun;13(4):387–395.
   PubMed Web of Science ®Google Scholar
• Pratt LA, Brody DJ. Depression and obesity in the U.S. adult household population, 2005-2010. NCHS Data Brief. 2014 Oct;(167):1–8.
   Google Scholar
• Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006 Apr 5;295(13):1549–1555.
   PubMed Web of Science ®Google Scholar
• Compton WM, Conway KP, Stinson FS, et al. Changes in the prevalence of major depression and comorbid substance use disorders in the United States between 1991-1992 and 2001-2002. Am J Psychiatry. 2006 Dec;163(12):2141–2147.
   PubMed Web of Science ®Google Scholar
• Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006 Aug 24;355(8):763–778.
   PubMed Web of Science ®Google Scholar
• Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001 Sep;58(9):844–850.
   PubMed Web of Science ®Google Scholar
• Loeppke R, Taitel M, Richling D, et al. Health and productivity as a business strategy. J Occup Environ Med. 2007 Jul;49(7):712–721.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Kotwal R, Keck PE. Medical management of obesity associated with mood disorders. In: McElroy SL, Allison DB, Bray GA, editors. Obesity and mental disorders. New York (NY): Taylor & Francis Group; 2006. p. 369–415.
   Google Scholar
• McElroy SL, Guerdjikova AI, Kim DD, et al. Naltrexone/bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study. Prim Care Companion CNS Disord. 2013;15(3).
   PubMedGoogle Scholar
• Lopresti AL, Drummond PD. Obesity and psychiatric disorders: commonalities in dysregulated biological pathways and their implications for treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug;1(45):92–99.
   Web of Science ®Google Scholar
• Henderson DC, Vincenzi B, Andrea NV, et al. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry. 2015 May;2(5):452–464.
   PubMed Web of Science ®Google Scholar
• Lasserre AM, Glaus J, Vandeleur CL, et al. Depression with atypical features and increase in obesity, body mass index, waist circumference, and fat mass: a prospective, population-based study. JAMA Psychiatry. 2014 Aug;71(8):880–888.
   PubMed Web of Science ®Google Scholar
• Boudebesse C, Geoffroy PA, Henry C, et al. Links between sleep and body mass index in bipolar disorders: an exploratory study. Eur Psychiatry. 2015 Jan;30(1):89–93.
   PubMed Web of Science ®Google Scholar
• Samaan Z, Lee YK, Gerstein HC, et al. Obesity genes and risk of major depressive disorder in a multiethnic population: a cross-sectional study. J Clin Psychiatry. 2015 Dec;76(12):e1611–8.
   Google Scholar
• Hung CF, Breen G, Czamara D, et al. A genetic risk score combining 32 SNPs is associated with body mass index and improves obesity prediction in people with major depressive disorder. BMC Med. 2015;13:86.
   PubMed Web of Science ®Google Scholar
• Cuellar-Barboza AB, Winham SJ, McElroy SL, et al. Accumulating evidence for a role of TCF7L2 variants in bipolar disorder with elevated body mass index. Bipolar Disord. 2016 Mar;18(2):124–135.
   PubMed Web of Science ®Google Scholar
• Dent R, Blackmore A, Peterson J, et al. Changes in body weight and psychotropic drugs: a systematic synthesis of the literature. PLoS One. 2012;7(6):e36889.
   Google Scholar
• Correll CU, Detraux J, De Lepeleire J, et al. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015 Jun;14(2):119–136.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund PA, Chiu WT, et al. The prevalence and correlates of binge eating disorder in the World Health Organization world mental health surveys. Biol Psychiatry. 2013 Jan 3;73(9):904–914.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Crow S, Blom TJ, et al. Prevalence and correlates of DSM-5 eating disorders in patients with bipolar disorder. J Affect Disord. 2016;191:216–221.
   PubMed Web of Science ®Google Scholar
• Sonneville KR, Horton NJ, Micali N, et al. Longitudinal associations between binge eating and overeating and adverse outcomes among adolescents and young adults: does loss of control matter? JAMA Ped. 2013 Feb;167(2):149–155.
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Kupfer DJ, Houck PR, et al. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry. 2003 Jan;160(1):112–117.
   PubMed Web of Science ®Google Scholar
• Opel N, Redlich R, Grotegerd D, et al. Obesity and major depression: body-mass index (BMI) is associated with a severe course of disease and specific neurostructural alterations. Psychoneuroendocrinology. 2014 Oct 13;51C:219–226.
   Google Scholar
• McElroy SL, Kemp DE, Friedman ES, et al. Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder. Acta Psychiatr Scand. 2015 Jun 26.
   PubMed Web of Science ®Google Scholar
• Bond DJ, Andreazza AC, Hughes J, et al. Association of peripheral inflammation with body mass index and depressive relapse in bipolar disorder. Psychoneuroendocrinology. 2016;65:76–83.
   PubMed Web of Science ®Google Scholar
• Kolotkin RL, Corey-Lisle PK, Crosby RD, et al. Impact of obesity on health-related quality of life in schizophrenia and bipolar disorder. Obesity (Silver Spring). 2008 Apr;16(4):749–754.
   PubMed Web of Science ®Google Scholar
• Shelton RC, Falola M, Li L, et al. The pro-inflammatory profile of depressed patients is (partly) related to obesity. J Psychiatr Res. 2015;70:91–97.
   PubMed Web of Science ®Google Scholar
• Bond DJ, Lang DJ, Noronha MM, et al. The association of elevated body mass index with reduced brain volumes in first-episode mania. Biol Psychiatry. 2011 Aug 15;70(4):381–387.
   PubMed Web of Science ®Google Scholar
• Bond DJ, da Silveira LE, MacMillan EL, et al. Relationship between body mass index and hippocampal glutamate/glutamine in bipolar disorder. Br J Psychiatry. 2016 Feb;208(2):146–152.
   PubMed Web of Science ®Google Scholar
• Woo YS, Seo HJ, McIntyre RS, et al. Obesity and its potential effects on antidepressant treatment outcomes in patients with depressive disorders: a literature review. Int J Mol Sci. 2016 Jan 12;17(1).
   Web of Science ®Google Scholar
• Fabricatore AN, Wadden TA, Higginbotham AJ, et al. Intentional weight loss and changes in symptoms of depression: a systematic review and meta-analysis. Int J Obes (Lond). 2011 Nov;35(11):1363–1376.
   PubMed Web of Science ®Google Scholar
• Mitchell JE, King WC, Chen JY, et al. Course of depressive symptoms and treatment in the longitudinal assessment of bariatric surgery (LABS-2) study. Obesity (Silver Spring). 2014 Aug;22(8):1799–1806.
   PubMed Web of Science ®Google Scholar
• Rubin RR, Wadden TA, Bahnson JL, et al. Impact of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: the Look AHEAD Trial. Diabetes Care. 2014 Jun;37(6):1544–1553.
   PubMed Web of Science ®Google Scholar
• Jenkins I, Djuric Z, Darga L, et al. Relationship of psychiatric diagnosis and weight loss maintenance in obese breast cancer survivors. Obes Res. 2003 Nov;11(11):1369–1375.
   PubMedGoogle Scholar
• Pagoto S, Bodenlos JS, Kantor L, et al. Association of major depression and binge eating disorder with weight loss in a clinical setting. Obesity (Silver Spring). 2007 Nov;15(11):2557–2559.
   PubMed Web of Science ®Google Scholar
• Pagoto S, Schneider KL, Whited MC, et al. Randomized controlled trial of behavioral treatment for comorbid obesity and depression in women: the Be Active Trial. Int J Obes (Lond). 2013 Nov;37(11):1427–1434.
   PubMed Web of Science ®Google Scholar
• Klem ML, Wing RR, McGuire MT, et al. Psychological symptoms in individuals successful at long-term maintenance of weight loss. Health Psychol. 1998 Jul;17(4):336–345.
   PubMed Web of Science ®Google Scholar
• Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010 Oct;71(10):1259–1272.
   PubMed Web of Science ®Google Scholar
• Tarricone I, Ferrari Gozzi B, Serretti A, et al. Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychol Med. 2010 Feb;40(2):187–200.
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Hansen RA, Morgan LC, et al. Second-generation antidepressants in the pharmacologic treatment of adult depression: an update of the 2007 comparative effectiveness review. Rockville (MD): Agency for Health Care Research and Quality; 2011.
   Google Scholar
• De Hert M, Yu W, Detraux J, et al. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012 Sep 1;26(9):733–759.
   PubMed Web of Science ®Google Scholar
• Pickrell WO, Lacey AS, Thomas RH, et al. Weight change associated with antiepileptic drugs. J Neurol Neurosurg Psychiatry. 2013 Jul;84(7):796–799.
   PubMed Web of Science ®Google Scholar
• Bak M, Fransen A, Janssen J, et al. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One. 2014;9(4):e94112.
   PubMed Web of Science ®Google Scholar
• Fernstrom MH, Kupfer DJ. Antidepressant-induced weight gain: a comparison study of four medications. Psychiatry Res. 1988 Dec;26(3):265–271.
   PubMed Web of Science ®Google Scholar
• Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. J Clin Psychiatry. 2001 Apr;62(4):256–260.
   PubMed Web of Science ®Google Scholar
• Kraus T, Haack M, Schuld A, et al. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry. 2002 Nov;35(6):220–225.
   PubMed Web of Science ®Google Scholar
• Uher R, Mors O, Hauser J, et al. Changes in body weight during pharmacological treatment of depression. Int J Neuropsychopharmacol. 2011 Apr;14(3):367–375.
   PubMed Web of Science ®Google Scholar
• Citrome L. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant–what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2013 Nov;67(11):1089–1104.
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Chrones L, Florea I, et al. The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol. 2016 Mar;30(3):242–252.
   PubMed Web of Science ®Google Scholar
• Singh M, Schwartz TL. Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use. Neuropsychiatr Dis Treat. 2012;8:123–130.
   PubMed Web of Science ®Google Scholar
• Harto NE, Spera KF, Branconnier RJ. Fluoxetine-induced reduction of body mass in patients with major depressive disorder. Psychopharmacol Bull. 1988;24(2):220–223.
   PubMedGoogle Scholar
• Harto-Traux N, Stem WC, Miller LL, et al. Effects of bupropion on body weight. J Clin Psychiatry. 1983;44:183–186.
   PubMed Web of Science ®Google Scholar
• Settle EC, Stahl SM, Batey SR, et al. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther. 1999 Mar;21(3):454–463.
   PubMed Web of Science ®Google Scholar
• Croft H, Houser TL, Jamerson BD, et al. Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks. Clin Ther. 2002 Apr;24(4):662–672.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Mancini DA, McCann S, et al. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord. 2002 Jun;4(3):207–213.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Fayyad RS, Guico-Pabia CJ, et al. A post hoc analysis of the effect of weight on efficacy in depressed patients treated with desvenlafaxine 50 mg/d and 100 mg/d. Prim Care Companion CNS Disord. 2015 Jun 4;17(3).
   Google Scholar
• Wise TN, Perahia DG, Pangallo BA, et al. Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies. Prim Care Companion J Clin Psychiatry. 2006;8(5):269–278.
   PubMedGoogle Scholar
• Rudolph RL, Fabre LF, Feighner JP, et al. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry. 1998 Mar;59(3):116–122.
   PubMed Web of Science ®Google Scholar
• Fava M, Judge R, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry. 2000 Nov;61(11):863–867.
   PubMed Web of Science ®Google Scholar
• Michelson D, Amsterdam JD, Quitkin FM, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry. 1999 Aug;156(8):1170–1176.
   PubMed Web of Science ®Google Scholar
• Gibson-Smith D, Bot M, Milaneschi Y, et al. Major depressive disorder, antidepressant use, and subsequent 2-year weight change patterns in the Netherlands Study of Depression and Anxiety. J Clin Psychiatry. 2016 Feb;77(2):e144–e151.
   Google Scholar
• Uguz F, Sahingoz M, Gungor B, et al. Weight gain and associated factors in patients using newer antidepressant drugs. Gen Hosp Psychiatry. 2015 Jan-Feb;37(1):46–48.
   PubMed Web of Science ®Google Scholar
• Blumenthal SR, Castro VM, Clements CC, et al. An electronic health records study of long-term weight gain following antidepressant use. JAMA Psychiatry. 2014 Aug;71(8):889–896.
   PubMed Web of Science ®Google Scholar
• Levine LR, Enas GG, Thompson WL, et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study (with a commentary by Michael Weintraub). Int J Obes. 1989;13(5):635–645.
   PubMed Web of Science ®Google Scholar
• Darga LL, Carroll-Michals L, Botsford SJ, et al. Fluoxetine’s effect on weight loss in obese subjects. Am J Clin Nutr. 1991 Aug;54(2):321–325.
   PubMed Web of Science ®Google Scholar
• Wise SD. Clinical studies with fluoxetine in obesity. Am J Clin Nutr. 1992 Jan;55(1Suppl):181S–184S.
   Google Scholar
• Goldstein DJ, Rampey AH Jr., Enas GG, et al. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes Relat Metab Disord. 1994 Mar;18(3):129–135.
   PubMed Web of Science ®Google Scholar
• Gadde KM, Parker CB, Maner LG, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res. 2001 Sep;9(9):544–551.
   PubMedGoogle Scholar
• Anderson JW, Greenway FL, Fujioka K, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res. 2002 Jul;10(7):633–641.
   PubMedGoogle Scholar
• Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res. 2002 Oct;10(10):1049–1056.
   PubMedGoogle Scholar
• Greenway FL, Dunayevich E, Tollefson G, et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab. 2009 Dec;94(12):4898–4906.
   PubMed Web of Science ®Google Scholar
• Norris SL, Zhang X, Avenell A, et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med. 2004 Jul 12;164(13):1395–1404.
   PubMedGoogle Scholar
• Abell CA, Farquhar DL, Galloway SM, et al. Placebo controlled double-blind trial of fluvoxamine maleate in the obese. J Psychosom Res. 1986;30(2):143–146.
   PubMed Web of Science ®Google Scholar
• Szkudlarek J, Elsborg L. Treatment of severe obesity with a highly selective serotonin re-uptake inhibitor as a supplement to a low calorie diet. Int J Obes Relat Metab Disord. 1993 Dec;17(12):681–683.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Bartlett SJ, Foster GD, et al. Sertraline and relapse prevention training following treatment by very-low-calorie diet: a controlled clinical trial. Obes Res. 1995 Nov;3(6):549–557.
   PubMedGoogle Scholar
• Mathew B, Rao JM, Sundari U. Lithium-induced changes in the body mass index. Acta Psychiatr Scand. 1989 Dec;80(6):538–540.
   PubMed Web of Science ®Google Scholar
• Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex maintenance study group. Arch Gen Psychiatry. 2000 May;57(5):481–489.
   PubMed Web of Science ®Google Scholar
• Sachs G, Bowden C, Calabrese JR, et al. Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disord. 2006 Apr;8(2):175–181.
   PubMed Web of Science ®Google Scholar
• Bowden CL, Calabrese JR, Ketter TA, et al. Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. Am J Psychiatry. 2006 Jul;163(7):1199–1201.
   PubMed Web of Science ®Google Scholar
• Wang PW, Ketter TA. Clinical use of carbamazepine for bipolar disorders. Expert Opin Pharmacother. 2005 Dec;6(16):2887–2902.
   PubMed Web of Science ®Google Scholar
• Merideth CH. A single-center, double-blind, placebo-controlled evaluation of lamotrigine in the treatment of obesity in adults. J Clin Psychiatry. 2006 Feb;67(2):258–262.
   PubMed Web of Science ®Google Scholar
• Findling RL, Robb A, McNamara NK, et al. Lithium in the acute treatment of bipolar I disorder: a double-blind, placebo-controlled study. Pediatrics. 2015 Nov;136(5):885–894.
   PubMed Web of Science ®Google Scholar
• Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015 Feb;100(2):342–362.
   PubMed Web of Science ®Google Scholar
• Bray GA, Fruhbeck G, Ryan DH, et al. Management of obesity. Lancet. 2016 May 7;387(10031):1947–1956.
   Web of Science ®Google Scholar
• Novo Nordisk. Full prescribing guidelines for Saxenda; 2014. Available from: http://www.novo-pi.com/saxenda.pdf
   Google Scholar
• Eisai. Full prescribing guidelines for Locaserin; 2012. Available from: https://www.belviq.com/documents/Belviq_Prescribing_information.pdf
   Google Scholar
• Genentech. Full prescribing guidelines for orlistat; 1999. Available from: http://www.gene.com/download/pdf/xenical_prescribing.pdf
   Google Scholar
• Vivus. Full prescribing guidelines for Qsymia; 2014. Available from: https://qsymia.com/pdf/prescribing-information.pdf
   Google Scholar
• Takeda. Full prescribing guidelines for Contrave; 2014. Available from: http://general.takedapharm.com/content/file.aspx?filetypecode=CONTRAVEPI&cacheRandomizer=e7a742c0-ae71-4c14-93ed-266e21a562ec
   Google Scholar
• Anon. benzphetamine prescribing information; [cited 2016 Mar 23]. Available from: www.drugs.com/pro/benzphetamine.html
   Google Scholar
• Anon. diethylpropion prescribing information; [cited 2016 Mar 23]. Available from: www.drugs.com/pro/diethylpropion.html
   Google Scholar
• Anon. phendimetrazine prescribing information; [cited 2016 Mar 23]. Available from: www.drugs.com/pro/phendimetrazine.html
   Google Scholar
• Anon. phentermine prescribing information; [cited 2016 Mar 23]. Available from: www.drugs.com/pro/phentermine.html
   Google Scholar
• Maglione M, Miotto K, Iguchi M, et al. Psychiatric effects of ephedra use: an analysis of food and drug administration reports of adverse events. Am J Psychiatry. 2005 Jan;162(1):189–191.
   PubMed Web of Science ®Google Scholar
• Bersani FS, Coviello M, Imperatori C, et al. Adverse psychiatric effects associated with herbal weight-loss products. Biomed Res Int. 2015;2015:120679.
   PubMed Web of Science ®Google Scholar
• Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007 Nov 17;370(9600):1706–1713.
   PubMed Web of Science ®Google Scholar
• Grant P, Lipscomb D, Quin J. Psychological and quality of life changes in patients using GLP-1 analogues. J Diabetes Complications. 2011 Jul-Aug;25(4):244–246.
   PubMed Web of Science ®Google Scholar
• Benazzi F. Depression induced by orlistat (Xenical). Can J Psychiatry. 2000 Feb;45(1):87.
   PubMed Web of Science ®Google Scholar
• Kiortsis DN, Tsouli S, Filippatos TD, et al. Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study. Nutr Metab Cardiovasc Dis. 2008 Mar;18(3):207–210.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski KE, Prcela L, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA. 2016 Mar 8;315(10):990–1004.
   PubMed Web of Science ®Google Scholar
• Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry. 2006 Feb;163(2):232–239.
   PubMed Web of Science ®Google Scholar
• Fogelson DL, Bystritsky A, Pasnau R. Bupropion in the treatment of bipolar disorders: the same old story? J Clin Psychiatry. 1992 Dec;53(12):443–446.
   PubMed Web of Science ®Google Scholar
• Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013 Nov;170(11):1249–1262.
   PubMed Web of Science ®Google Scholar
• Devan GS. Phentermine and psychosis. Br J Psychiatry. 1990 Mar;156:442–443.
   PubMed Web of Science ®Google Scholar
• Alexander J, Cheng YH, Choudhary J, et al. Phentermine (Duromine) precipitated psychosis. Aust N Z J Psychiatry. 2011 Aug;45(8):684–685.
   PubMed Web of Science ®Google Scholar
• Celano CM, Freudenreich O, Fernandez-Robles C, et al. Depressogenic effects of medications: a review. Dialogues Clin Neurosci. 2011;13(1):109–125.
   PubMedGoogle Scholar
• Siamouli M, Samara M, Fountoulakis KN. Is antiepileptic-induced suicidality a data-based class effect or an exaggeration? A comment on the literature. Harv Rev Psychiatry. 2014 Nov-Dec;22(6):379–381.
   PubMed Web of Science ®Google Scholar
• Nickel C, Lahmann C, Tritt K, et al. Topiramate in treatment of depressive and anger symptoms in female depressive patients: a randomized, double-blind, placebo-controlled study. J Affect Disord. 2005 Aug;87(2–3):243–252.
   PubMed Web of Science ®Google Scholar
• Mowla A, Kardeh E. Topiramate augmentation in patients with resistant major depressive disorder: a double-blind placebo-controlled clinical trial. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):970–973.
   PubMed Web of Science ®Google Scholar
• Roy Chengappa KN, Schwarzman LK, Hulihan JF, et al. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial. J Clin Psychiatry. 2006 Nov;67(11):1698–1706.
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Cutler AJ, Richards C, et al. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram. J Clin Psychiatry. 2013 Aug;74(8):802–809.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Alsuwaidan M, Soczynska JK, et al. The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder. Hum Psychopharmacol. 2013 Sep;28(5):421–427.
   PubMed Web of Science ®Google Scholar
• Madhoo M, Keefe RS, Roth RM, et al. Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. Neuropsychopharmacology. 2014 May;39(6):1388–1398.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Martens BE, Mori N, et al. Adjunctive lisdexamfetamine in bipolar depression: a preliminary randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2015 Jan;30(1):6–13.
   PubMed Web of Science ®Google Scholar
• Rickels K, Hesbacher P, Fisher E, et al. Emotional symptomatology in obese patients treated with fenfluramine and dextroamphetamine. Psychol Med. 1976 Nov;6(4):623–630.
   PubMed Web of Science ®Google Scholar
• Solati Z, Jazayeri S, Tehrani-Doost M, et al. Zinc monotherapy increases serum brain-derived neurotrophic factor (BDNF) levels and decreases depressive symptoms in overweight or obese subjects: a double-blind, randomized, placebo-controlled trial. Nutr Neurosci. 2015 May;18(4):162–168.
   PubMed Web of Science ®Google Scholar
• Jorde R, Sneve M, Figenschau Y, et al. Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial. J Intern Med. 2008 Dec;264(6):599–609.
   PubMed Web of Science ®Google Scholar
• Esmaily H, Sahebkar A, Iranshahi M, et al. An investigation of the effects of curcumin on anxiety and depression in obese individuals: a randomized controlled trial. Chin J Integr Med. 2015 May;21(5):332–338.
   PubMed Web of Science ®Google Scholar
• Shelton RC, Pencina MJ, Barrentine LW, et al. Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs. J Clin Psychiatry. 2015 Dec;76(12):1635–1641.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Guerdjikova AI, Mori N, et al. Current pharmacotherapy options for bulimia nervosa and binge eating disorder. Expert Opin Pharmacother. 2012 Oct;13(14):2015–2026.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Guerdjikova AI, Mori N, et al. Overview of the treatment of binge eating disorder. CNS Spectr. 2015 Dec;20(6):546–556.
   PubMed Web of Science ®Google Scholar
• Guerdjikova AI, McElroy SL, Winstanley EL, et al. Duloxetine in the treatment of binge eating disorder with depressive disorders: a placebo-controlled trial. Int J Eat Disord. 2012 Jul;8(45):281–289.
   Web of Science ®Google Scholar
• White MA, Grilo CM. Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2013;74(4):400–406.
   PubMed Web of Science ®Google Scholar
• Vyvanse® (lisdexamfetamine dimesylate). Full prescribing information. Wayne (PA): Shire US Inc.; 2015.
   Google Scholar
• Golay A, Laurent-Jaccard A, Habicht F, et al. Effect of orlistat in obese patients with binge eating disorder. Obes Res. 2005 Oct;13(10):1701–1708.
   PubMedGoogle Scholar
• Grilo CM, Masheb RM, Salant SL. Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry. 2005 May 15;57(10):1193–1201.
   PubMed Web of Science ®Google Scholar
• Malhotra S, McElroy SL. Orlistat misuse in bulimia nervosa. Am J Psychiatry. 2002 Mar;159(3):492–493.
   PubMed Web of Science ®Google Scholar
• Robert SA, Rohana AG, Shah SA, et al. Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide - a pilot study. Obes Res Clin Pract. 2015 May-Jun;9(3):301–304.
   PubMed Web of Science ®Google Scholar
• Guerdjikova AI, Fitch A, McElroy SL. Successful treatment of binge eating disorder with combination phentermine/topiramate extended release. Prim Care Companion CNS Disord. 2015 Apr 2;17(2). [Epub ahead of print].
   PubMedGoogle Scholar
• Kluge M, Schuld A, Himmerich H, et al. Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J Clin Psychopharmacol. 2007 Dec;27(6):662–666.
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Suzuki T, Nakagawa A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2014;40(6):1385–1403.
   PubMed Web of Science ®Google Scholar
• Praharaj SK, Sharma PS. Amantadine for olanzapine-induced weight gain: a systematic review and meta-analysis of randomized placebo-controlled trials. Ther Adv Psychopharmacol. 2012 Aug;2(4):151–156.
   PubMedGoogle Scholar
• Tek C, Ratliff J, Reutenauer E, et al. A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept. J Clin Psychopharmacol. 2014 Oct;34(5):608–612.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Winstanley E, Mori N, et al. A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain. J Clin Psychopharmacol. 2012 Apr;32(2):165–172.
   PubMed Web of Science ®Google Scholar
• Henderson DC, Kunkel L, Nguyen DD, et al. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand. 2006 Feb;113(2):142–147.
   PubMed Web of Science ®Google Scholar
• Tchoukhine E, Takala P, Hakko H, et al. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial. J Clin Psychiatry. 2011 Mar;72(3):326–330.
   PubMed Web of Science ®Google Scholar
• Sletten IW, Ognjanov V, Menendez S, et al. Weight reduction with chlorphenetermine and phenmetrazine in obese psychiatric patients during chlorpromazine therapy. Curr Ther Res Clin Exp. 1967 Nov;9(11):570–575.
   PubMed Web of Science ®Google Scholar
• Ishoy PL, Knop FK, Vilsboll T, et al. Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes. Am J Psychiatry. 2013 Jun;170(6):681–682.
   PubMed Web of Science ®Google Scholar